Company: AptamiR Therapeutics

Job title: Founder & President


Active Cellular Targeting miRNA Oligonucleotide Therapeutics (ONTs) to Treat Metabolic Pandemics 11:00 am

Discovery and validation of miR-22-3p as an excellent metabolic miRNA In silico, in vitro and in vivo validation of miR-22-3p antagomirs to treat obesity, MAFLD and related cardiometabolic disorders Current preclinical validation of Generation 2.5 miR-22-3p antagomirs for enhanced active targeted delivery of a greatly reduced therapeutic dose with an extended intracellular Mean Residence TimeRead more

day: Seminar A- AM tracks

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.